COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 42, Issue 3, Pages 284-292
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-04-14
DOI
10.1097/jcp.0000000000001543
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Is a Diagnosis of Schizophrenia Spectrum Disorder Associated With Increased Mortality in Patients With COVID-19?
- (2022) Marina Sánchez-Rico et al. AMERICAN JOURNAL OF PSYCHIATRY
- Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS‐CoV‐2 infection?
- (2021) Pascal Le Corre et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
- (2021) Nicolas Hoertel et al. MOLECULAR PSYCHIATRY
- A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders
- (2021) Ahmad A. Toubasi et al. PSYCHIATRY RESEARCH
- Severe mental illness is associated with increased mortality and severe course of COVID‐19
- (2021) Carlo Alberto Barcella et al. ACTA PSYCHIATRICA SCANDINAVICA
- Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID‐19 Spanish inpatients
- (2021) Crisanto Diez‐Quevedo et al. ACTA PSYCHIATRICA SCANDINAVICA
- Metabolic Signatures Associated with Severity in Hospitalized COVID-19 Patients
- (2021) Judith Marín-Corral et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue
- (2021) Melissa Zimniak et al. Scientific Reports
- Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: An Observational Multicenter Study
- (2021) Nicolas Hoertel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Old drug fluvoxamine, new hope for COVID-19
- (2021) Yaeko Hashimoto et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
- (2021) Nicolas Hoertel et al. MOLECULAR PSYCHIATRY
- Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area
- (2021) Udo Bonnet et al. PHARMACOPSYCHIATRY
- Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
- (2021) Linda Brunotte et al. Pharmaceutics
- Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
- (2021) Shelley N. Facente et al. DRUGS
- Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature
- (2021) Enrica Torretta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
- (2021) Gilmar Reis et al. Lancet Global Health
- Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
- (2021) Nicolas Hoertel JAMA Network Open
- Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
- (2021) Tomiko Oskotsky et al. JAMA Network Open
- Longer-term mortality following SARS-CoV-2 infection in people with severe mental illness: retrospective case-matched study
- (2021) Shanquan Chen et al. BJPsych Open
- COVID-19, interferons, and depression: A commentary
- (2020) Richard I. Shader PSYCHIATRY RESEARCH
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
- (2020) Eric J. Lenze et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.
- (2020) Luana Lionetto et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
- (2019) Dorian A. Rosen et al. Science Translational Medicine
- The vagus nerve role in antidepressants action: Efferent vagal pathways participate in peripheral anti-inflammatory effect of fluoxetine
- (2019) Katarina Ondicova et al. NEUROCHEMISTRY INTERNATIONAL
- The sour side of vitamin C might mediate neuroprotective, anticonvulsive and antidepressant-like effects
- (2019) Udo Bonnet MEDICAL HYPOTHESES
- Identification of Novel Functional Inhibitors of Acid Sphingomyelinase
- (2011) Johannes Kornhuber et al. PLoS One
- Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications
- (2010) Johannes Kornhuber et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro
- (2009) Udo Bonnet et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search